基于FDA不良事件报告系统的安全分析
Meijuan Song1, Jian Xie, Liyuan Yang
1Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong, China.
这项研究使用FAERS数据分析了ramucirumab不良事件 (AEs). 虽然许多副作用与药物标签一致,但发现了诸如发炎性粒瘤等新的安全信号,需要加强临床警.
科学领域:
- 药物监督管理
- 药物安全
- 癌症治疗药物
背景情况:
- 拉穆西鲁马布是一种用于癌症治疗的血管生成抑制剂.
- 对于了解与药物相关的不良事件至关重要的是现实安全数据.
- 美国食品和药物管理局 (FDA) 的不良事件报告系统 (FAERS) 为药监提供了宝贵的信息来源.
研究的目的:
- 识别和分析拉穆西鲁马布的不良反应信号.
- 将现实世界中的AE信号与现有的药物标签进行比较.
- 为了支持拉穆西鲁马布的临床安全性.
主要方法:
- 使用FAERS数据库和Open Vigil 2.1进行数据提取.
- 使用统计方法,包括报告概率 (ROR),比例报告比率 (PRR) 和贝叶斯信任传播神经网络 (BCPNN) 来检测信号.
- 根据"监管活动医学词典"的优先术语 (PT) 和系统器官类 (SOC) 进行了AE分类.
主要成果:
- 分析了1701份与拉穆西鲁马布相关的副作用报告.
- 在18个SOC中确定了130个PT信号;72个PT不在药物标签上.
- 证实了已知的副作用,如高血压和中性质减退,并确定了潜在的新信号,包括发热性颗粒瘤和间歇性肺病.
结论:
- 在现实世界中,ramucirumab的副作用大多与标记事件相匹配.
- 新的,可能严重的AE需要进一步调查.
- 建议加强临床监测和风险评估,以确保患者的安全.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
Clinical Trials: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Clinical Trials
There are four phases in a clinical trial. A phase one...
